Zolotov Sergey A, Demina Natalia B, Zolotova Anna S, Shevlyagina Natalia V, Buzanov Grigorii A, Retivov Vasilii M, Kozhukhova Evgeniia I, Zakhoda Oleg Y, Dain Igor A, Filatov Andrei R, Cheremisin Alexander M
Amedart LLC, Moscow, Russia.
Department of Pharmaceutical Technology Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russia.
Eur J Pharm Sci. 2021 Apr 1;159:105700. doi: 10.1016/j.ejps.2021.105700. Epub 2021 Jan 8.
The aim of this work was to compare mesoporous carriers based on silica and magnesium aluminosilicate in the amorphous solid dispersion production. Darunavir has been selected as an active pharmaceutical ingredient that is classified as a Class 2 BCS substance and exists in two commercially available forms: crystalline ethanolate and amorphous. In the course of the study, the conditions for the preparation of amorphous samples with the selected carriers were evaluated within the framework of the most common methods for obtaining solid dispersions - hot-melt extrusion, solvent wetting, and spray drying. It was determined that the obtained dispersion properties almost completely repeat the properties of the corresponding carriers. The resulting dispersions were examined in a dissolution test and the best ones was used to formulate tablets, which were studied in an in vitro dissolution test with the original Prezista. The proposed tablet formulation showed improved dissolution compared to the original one. It was also found that silica supports have a greater positive contribution to darunavir dissolution - both ethanolate or amorphous forms.
这项工作的目的是在无定形固体分散体生产中比较基于二氧化硅和镁铝硅酸盐的介孔载体。已选择达芦那韦作为活性药物成分,它被归类为2类BCS物质,有两种市售形式:结晶乙醇酸盐和无定形。在研究过程中,在获得固体分散体的最常用方法——热熔挤出、溶剂湿润和喷雾干燥的框架内,评估了用选定载体制备无定形样品的条件。已确定所获得的分散体性质几乎完全重复相应载体的性质。对所得分散体进行溶出度试验,并使用最佳分散体制备片剂,在体外溶出度试验中与原Prezista进行比较研究。所提出的片剂配方显示出比原配方更好的溶出度。还发现二氧化硅载体对达芦那韦的溶出有更大的积极作用——无论是乙醇酸盐形式还是无定形形式。